CN Patent

CN105237571B — 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐

Assigned to Chengdu Easton Biopharmaceuticals Co Ltd · Expires 2018-03-09 · 8y expired

What this patent protects

本发明涉及一种9‑[(R)‑2‑[[(S)‑[[(S)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的药学上可接受的盐，本发明制备的替诺福韦艾拉酚胺半琥珀酸盐和半酒石酸盐均显示了良好的稳定性，和更高的最大血药浓度和更好的吸收。

USPTO Abstract

本发明涉及一种9‑[(R)‑2‑[[(S)‑[[(S)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的药学上可接受的盐，本发明制备的替诺福韦艾拉酚胺半琥珀酸盐和半酒石酸盐均显示了良好的稳定性，和更高的最大血药浓度和更好的吸收。

Drugs covered by this patent

Patent Metadata

Patent number
CN105237571B
Jurisdiction
CN
Classification
—
Expires
2018-03-09
Drug substance claim
No
Drug product claim
No
Assignee
Chengdu Easton Biopharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.